1
Clinical Trials associated with Insulin Glargine Biosimilar (Xentria)Single-dose, Double-blind, Randomized, Three-period, Three-treatment, Six-sequence, Crossover Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(G), US-Lantus®, and EU-Lantus®
Single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®
100 Clinical Results associated with Insulin Glargine Biosimilar (Xentria)
100 Translational Medicine associated with Insulin Glargine Biosimilar (Xentria)
100 Patents (Medical) associated with Insulin Glargine Biosimilar (Xentria)
100 Deals associated with Insulin Glargine Biosimilar (Xentria)